These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 38466028

  • 21. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P.
    J Headache Pain; 2019 Jan 16; 20(1):6. PubMed ID: 30651064
    [Abstract] [Full Text] [Related]

  • 22. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y, Liu L.
    Cephalalgia; 2019 Aug 16; 39(9):1164-1179. PubMed ID: 30789292
    [Abstract] [Full Text] [Related]

  • 23. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 16; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 24. Galcanezumab for the prevention of migraine.
    Frerichs LM, Friedman DI.
    Pain Manag; 2021 Mar 16; 11(2):101-112. PubMed ID: 33291980
    [Abstract] [Full Text] [Related]

  • 25. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S.
    Expert Rev Neurother; 2020 Jun 16; 20(6):627-641. PubMed ID: 32434430
    [Abstract] [Full Text] [Related]

  • 26. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A, Pozo-Rosich P.
    Lancet; 2019 Nov 09; 394(10210):1765-1774. PubMed ID: 31668411
    [Abstract] [Full Text] [Related]

  • 27. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB.
    Neurology; 2020 May 19; 94(20):e2121-e2125. PubMed ID: 31932515
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
    Aleksovska K, Hershey AD, Deen M, Icco R, Lee MJ, Diener HC.
    Cephalalgia; 2023 Oct 19; 43(10):3331024231206162. PubMed ID: 37879637
    [Abstract] [Full Text] [Related]

  • 29. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
    Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C.
    J Headache Pain; 2022 Jun 11; 23(1):67. PubMed ID: 35690723
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J, Pascual-Morena C, Flor-García A, Saz-Lara A, Sequí-Dominguez I, Álvarez-Bueno C, Barreda-Hernández D, Cavero-Redondo I.
    Int J Environ Res Public Health; 2022 Feb 03; 19(3):. PubMed ID: 35162776
    [Abstract] [Full Text] [Related]

  • 34. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW.
    Cephalalgia; 2019 Mar 03; 39(3):445-458. PubMed ID: 30661365
    [Abstract] [Full Text] [Related]

  • 35. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.
    Eur J Neurol; 2023 Jun 03; 30(6):1764-1773. PubMed ID: 36856538
    [Abstract] [Full Text] [Related]

  • 36. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, Lu J, Wade RL, Frerichs L, Bensink ME.
    J Headache Pain; 2023 Nov 09; 24(1):153. PubMed ID: 37946113
    [Abstract] [Full Text] [Related]

  • 37. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R, Russo CV.
    Headache; 2023 Jun 09; 63(6):788-794. PubMed ID: 37254581
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K, Michael RL, Rapoport AM.
    Drugs; 2018 Jun 09; 78(9):913-928. PubMed ID: 29869205
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.